9-(8-Bromo-dibenzofuran-2-yl)-9H-carbazole

We are 9-(8-Bromo-dibenzofuran-2-yl)-9H-carbazole CAS:1100750-07-5 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:9-(8-Bromo-dibenzofuran-2-yl)-9H-carbazole
CAS.NO:1100750-07-5
Synonyms:9-(8-Bromo-dibenzofuran-2-yl)-9H-carbazole
Molecular Formula:C24H14BrNO
Molecular Weight:412.27806
 
Specification:
Appearance:White powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:OLED intermediates

9-(8-Bromo-dibenzofuran-2-yl)-9H-carbazole


Related News: “No two studies are the same, and each carries its own unique risks and presents individual challenges, but the aim of CTSuccess is to use the experience we have as a company in supplying materials for thousands of trials to identify the characteristics of a project upfront and highlight potential risk factors that may arise,” said Kristen Devito, Global Director, Catalent Clinical Supply Services.Ethyl 2,6-Dichloro-5-Fluoro-Pyridine-3-Acetoacetate “No two studies are the same, and each carries its own unique risks and presents individual challenges, but the aim of CTSuccess is to use the experience we have as a company in supplying materials for thousands of trials to identify the characteristics of a project upfront and highlight potential risk factors that may arise,” said Kristen Devito, Global Director, Catalent Clinical Supply Services.65376-05-8 “No two studies are the same, and each carries its own unique risks and presents individual challenges, but the aim of CTSuccess is to use the experience we have as a company in supplying materials for thousands of trials to identify the characteristics of a project upfront and highlight potential risk factors that may arise,” said Kristen Devito, Global Director, Catalent Clinical Supply Services.3-Bromophenylboronic acid Mankind Pharmaceuticals on Monday said it has inked a licensing pact with Glenmark Pharmaceuticals to co-market diabetes drug Remogliflozin Etabonate in the country.The foundational patent, which expires in 2034, is owned by MSK and is licensed exclusively to Fate Therapeutics for all human therapeutic uses.

Related Products
Product Name
4-Fluoro-3-nitrobenzotrifluoride View Details
Estratetraenol View Details
5-piperazin-1-yl-1-benzofuran-2-carboxamide View Details
2-Methylbenzotrifluoride manufacturer 9-Phenyl-9H-Carbazol-3-Ylboronic Acid manufacturer 2-Amino-4-bromobenzoic acid manufacturer 4-(benzyloxy)-3-[(1R)-3-(dipropan-2-ylamino)-1-phenylpropyl]benzoic acid manufacturer 4-chloropyridin-2-amine manufacturer